IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Joe-Marc ChauvinMignane KaOrnella PaglianoCarmine MennaQuanquan DingRichelle DeBlasioCindy SanderJiajie HouXian-Yang LiSoldano FerroneDiwakar DavarJoanne M JeterRobert J JohnstonAlan J KormanMark J SmythHassane M ZarourPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our findings support the development of novel combinatorial immunotherapy with IL15 and TIGIT blockade to promote NK-cell-mediated destruction of MHC class I-deficient melanoma, which are refractory to CD8+ T-cell-mediated immunity.See related commentary by Pietra et al., p. 5274.
Keyphrases